Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Adjuvant Chemotherapy and Pancreatic Adenocarcinoma
Ann Surg Oncol; ePub 2017 Jan 9; Bergquist, et al
Use of adjuvant chemotherapy did not vary by resection type, but it improved survival in people with pancreatic adenocarcinoma (PDAC) no matter which procedure was performed, according to an analysis involving more than 13,500 individuals.
Investigators identified patients with localized PDAC undergoing distal partial pancreatectomy (DPP; n=1,933) or pancreatoduodenectomy (PD; n=11,568) between 2004 and 2012, excluding neoadjuvant cases. They looked at factors linked with receiving adjuvant therapy, as well as overall survival. Among the results:
- DPP patients had fewer N1 lesions, less often positive margins, more minimally invasive resections, and shorter hospital stays.
- ~One-third of patients in each group received adjuvant chemotherapy.
- Procedure type was not independently linked with adjuvant chemotherapy.
- Patients who received adjuvant chemotherapy had improved unadjusted and adjusted overall survival vs surgery alone.
- Resection did not predict adjusted mortality.
Bergquist J, Ivanics T, Shubert C, et al. Type of resection (Whipple vs. Distal) does not affect the national failure to provide post-resection adjuvant chemotherapy in localized pancreatic cancer. [Published online ahead of print January 9, 2017]. Ann Surg Oncol. doi:10.1245/s10434-016-5762-6.